Singapore (ots/PRNewswire) - - LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research - Safety profile is favourable and consistent with previous HMTM studies - TauRx will now pursue ...
Petach Tikvah, Israel (ots/PRNewswire) - The latest geographic growth increases Medison's global footprint across 25 countries in four continents, further strengthening its commercial offering Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients ...
Tübingen (ots) - Acousia Therapeutics GmbH will be presenting data on the company’s clinical stage, first-in-class lead candidate ACOU085 at the Hanson Wade 2nd Inner Ear Therapeutics Summit to be held in person in Boston (MA) from June 20–23, 2022. ACOU085 is a proprietary, first-in-class, small-molecule ...
Tübingen (ots) - ACOU085, the lead candidate from Acousia Therapeutics, has been administered to the first patient with age-related hearing loss (presbycusis) in a Phase 1b clinical study in Germany. The pre-screening of patients matching the comprehensive in/exclusion criteria for the ongoing trial is almost ...
Nijmegen, Netherlands and Wedel, Germany (ots/PRNewswire) - SYD985 Marketing Authorization Application Soon to Be Submitted to the EMA Byondis B.V., an independent, Dutch clinical stage biopharmaceutical company creating precision medicines, has entered into a License and Collaboration Agreement and a Supply ...
Barcelona, Spain (ots/PRNewswire) - - The agreement with Dana-Farber Cancer Institute consists of using HER2DX®️ to analyze tumor samples from more than 500 patients with early-stage HER2+ breast cancer across three clinical trials (APT, ATEMPT, and DAPHNE). - The three completed studies were essential in establishing new anti-HER2-based treatment strategies for ...
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced that data from the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational ...
Tel Aviv, Israel (ots/PRNewswire) - BENDIT Technologies, a company focused on the development of a steerable microcatheter platform, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Bendit21 microcatheter for treatment in the neuro, peripheral, and coronary ...
Aberdeen, Scotland and Singapore (ots/PRNewswire) - - Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's - TauRx on track to announce top line results in May - Trial aims to confirm efficacy of first tau-based treatment for Alzheimer's TauRx Pharmaceuticals Ltd, a global leader in tau-based Alzheimer's Disease (AD) research, has announced that the last patient has completed ...
Parma, Italy (ots/PRNewswire) - - 2021 Turnover €2.42bn - up 8.6% - Internationally China up 22%, US up >10% - Continued focus on innovation: almost 20% of turnover invested in R&D - Chiesi recognised as Top Employer in eight markets and as Top Employer Europe for 10th consecutive year Growth continues at Chiesi, the international research-focussed pharmaceutical group and its 30 global affiliates with turnover at €2.42bn, up 8.6% vs 2020. Gross operating profit (EBITDA) ...
Newport Beach (ots) - Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor ...
Aachen, Germany, and Raleigh, North Carolina (ots) - Grünenthal and NovaQuest announced today that they have entered into an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin (RTX). The investigational medicine is being developed with the aim of providing patients ...
MoonLake Immunotherapeutics AG
Zug, Switzerland (ots/PRNewswire) - - This Phase 2 study represents an important step in hidradenitis suppurativa ("HS") clinical development, as it will be the first to use the higher clinical response level of HiSCR75 as the primary endpoint - Expected to enroll over 200 patients with moderate-to-severe HS to ...
Prague (ots/PRNewswire) - Zentiva is a major developer and producer of high-quality and affordable medicines in Europe. Zentiva will donate 100,000 packs of medicines to humanitarian aid programs targeted at helping the citizens of Ukraine. The medicines will include life-saving hospital medicines, cardiovascular medicines, pain medication, and anti-infectives. The ...
Lisbon, Portugal (ots/PRNewswire) - Hovione today announced that the Board of Directors and the shareholders have approved the appointment of Dr. Jean-Luc Herbeaux as Hovione's Chief Executive Officer, effective 1st April 2022. Guy Villax, who has been Hovione's CEO for the past 25 years will now serve as a Member of the Board and shareholder. During his tenure, Hovione grew tenfold. The company currently employs 2000 ...
Lisbon (ots/PRNewswire) - Hovione, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome®, Zerion´s proprietary solubility enhancement technology platform. Zerion´s innovative Dispersome® technology builds on a new ...
Boston, Reykjavik, Iceland and Berlin (ots/PRNewswire) - - UnitedHealth Group and Anthem veteran Pamela Stahl joins as Chief Commercial Officer (CCO) and President, North America to lead Sidekick's global commercial strategy, driving revenue growth with international pharmaceutical majors and U.S.-based payers. - Mitchell Mudra joins Sidekick from UnitedHealth Group as ...
Lausanne, Switzerland and Durban, South Africa (ots) - Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company and Aspen, a South African headquartered multinational pharmaceutical company announced today their partnership to launch Trelstar® (Triptorelin) in South Africa for the treatment of locally advanced and metastatic hormone dependent prostate ...
Harrow, England (ots/PRNewswire) - Sondelbay – is a self-administered, once-a-day subcutaneous injection for patients with osteoporosis using a pen device - Accord's fourth biosimilar, joins the company's established portfolio across Europe, and marks its first branded product in a new Bone Health franchise representing another great milestone in Accord's growing ...
Tübingen (ots) - Acousia Therapeutics GmbH – along with its partners from the Translational Hearing Research Group at the Tübingen Hearing Research Center (Department of Otolaryngology, Head and Neck Surgery, University of Tübingen) and Synovo GmbH (Tübingen) – will be presenting data on the the company’s ...
Prague (ots/PRNewswire) - The Top Employee Institute has certified Zentiva as a Top Employer. This prestigious award was received for Zentiva's exceptional standards across 6 Human Resources-domains in its home countries the Czech Republic and Romania. The assessment was covering 20 topics including People Strategy, Work Environment, Talent Acquisition, Learning, Well-being, Diversity & Inclusion, and many more. "I am ...
Paris (ots/PRNewswire) - - Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerated oncology strategy with the acquisition of ...
Tel Aviv, Israel (ots/PRNewswire) - DALI Medical Devices, an innovative developer and distributor of drug delivery devices, today announced the first commercial implementation of its SAN-Light passive safety needle. SAN-Light was chosen to be used with ADVANZ PHARMA's MYTOLAC®/MYRELEZ® - the first generic ...
Lausanne, Switzerland - San Francisco (ots) - Funding to support BIOiSIMTM computational platform to reduce the need for animal testing by selecting compounds showing promise to cure a disease prior to research in humans Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today their co-investment in California-based start-up VeriSIM Life’s ...
San Francisco, CA (ots) - Financing led by Morpheus Ventures supports further revenue growth for the company’s next-generation AI platform, redefining the preclinical translational drug development landscape by accurately predicting and accelerating clinical outcomes VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug ...
Fremont, Calif. and Cambridge, England (ots/PRNewswire) - Alamar Biosciences (Alamar), a platform company focused on transforming the field of proteomics to enable the early detection of cancer and other diseases, and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences research tools, today announced a strategic partnership to further understanding of ...
Heidelberg, Germany and Cambridge, Mass (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today announced key results of the second pivotal Phase 3 trial (ESSENCE-2) evaluating the investigational drug ...
Lausanne, Switzerland (ots) - Dose escalation, monotherapy trial launched to access the safety and preliminary anti-tumor activity of Debio 0123 in the treatment of advanced solid tumors Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today the first patient treated in the newly ...
Heidelberg, Germany, and Cambridge, Mass. (ots/PRNewswire) - Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol® water-free technology, today provided a development update on the phase 3 trial of SHR8058 eye drops (perfluorohexyloctane) for the ...